High Accuracy Nanopore Sequencing

NIH Pandemic-Era Grants

Pandemic Era Grants

2020

↗ Live URL (may be dead)

Document text

Principal Investigator: JENS  GUNDLACH
Organization: UNIVERSITY OF WASHINGTON
Fiscal Year: 2020
Award: $313,632
Funding agency: National Human Genome Research Institute

This project is an expansion of the scope of our current funding which was awarded to improve nanopore
sequencing. In the course of our research to improve nanopore DNA sequencing, we have discovered and
developed a new high-resolution single-molecule tool to observe the motion of helicases and polymerases. The
tool, which we called Single-molecule Picometer Resolution Nanopore Tweezers (SPRNT), is able to reveal the
single-nucleotide steps of helicases and polymerases at unprecedented detail. These enzyme steps are so small
(~0.3 nm) and fast (~ 1 ms) that no other existing single-molecule technique can resolve such motion in real time
and at physiological conditions. The genome of the SARS-CoV-2 virus encodes for an RNA-dependent RNA
polymerase, also known as non-structural protein 12 (nsp12), and a superfamily 1B helicase, known as nonstructural protein 13 (nsp13). Both of these enzymes are essential and specific to the in vivo replication of many
viruses, making this genomic replication machinery an ideal drug target. Several drug candidates to inhibit these
enzymes exist, however, none are as effective as they need to be to stem the tide of the current pandemic. Many
questions remain about how exactly these drugs interfere with the function of nsp12 or nsp13. SPRNT provides
an opportunity to answer these questions. We aim to use SPRNT to analyze the single-molecule motion of nsp12
and nsp13 in physiological conditions and in the presence of drugs against them. The exact knowledge of the
mechanisms by which various drugs inhibit nsp12 or nsp13 will enable more rational and rapid design of effective
antiviral drugs that have the potential to stop COVID-19.

Terms: <2019 novel coronavirus><2019-nCoV><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Award><Bioassay><Biologic Assays><Biological Assay><COVID-19><COVID19><DNA><DNA Helicases><DNA Sequence><DNA Unwinding Proteins><DNA seq><DNA sequencing><DNA unwinding enzyme><DNAseq><Deoxyribonucleic Acid><Drug Design><Drug Targeting><Drugs><EC 2.7.7.48><Enzyme Antagonist><Enzyme Gene><Enzyme Inhibitor><Enzyme Inhibitor Agent><Enzyme Inhibitor Drugs><Enzyme Kinetics><Enzymes><Exonuclease><Funding><GS-5734><Genome><Genomics><Grant><Kinetics><Knowledge><Measures><Medication><Methods><Monitor><Motion><Motor><Msec><NHGRI><National Center for Human Genome Research><National Human Genome Research Institute><Non-Polyadenylated RNA><Non-structural Protein><Nonstructural Protein><Nucleic Acids><Nucleotides><Pharmaceutic Preparations><Pharmaceutical Preparations><Physiologic><Physiological><Polymerase><Position><Positioning Attribute><Proteins><RNA><RNA Gene Products><RNA Replicase><RNA-Dependent RNA Polymerase><RNA-Directed RNA Polymerase><Research><Resolution><Ribonucleic Acid><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Severe acute respiratory syndrome coronavirus 2><Site><Techniques><Technology><Time><Viral><Viral Genome><Virus><Virus Replication><Wuhan coronavirus><anti-viral agents><anti-viral drugs><anti-virals><corona virus disease 2019><coronavirus disease 2019><design><designing><drug candidate><drug/agent><helicase><improved><in vivo><inhibitor><inhibitor/antagonist><insight><millisecond><nano pore><nanopore><pandemic><pandemic disease><premature><prematurity><prevent><preventing><remdesivir><single molecule><stem><tool><viral RNA><viral multiplication><viral replication><virus RNA><virus genome><virus multiplication>